SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

11/9/23 6:15:55 AM ET

Medical/Dental Instruments

Health Care

Get the next $NVCR alert in real time by email

SC 13G/A 1 novocure31102023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NOVOCURE LTD (Amendment no.4) ----------------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------------- (Title of Class of Securities) G6674U108 ----------------------------------------------------------------------- (CUSIP Number) 31 October 2023 ----------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No. G6674U108 _______________________________________________________________________ 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Baillie Gifford & Co (Scottish partnership) _______________________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a).................................................................... (b).................................................................... _______________________________________________________________________ 3. SEC Use Only _______________________________________________________________________ 4. Citizenship or Place of Organization SCOTLAND UK _______________________________________________________________________ Number of 5. Sole Voting Power 3,891,984 Shares Bene ______________________________________________________ ficially by 6. Shared Voting Power 0 Owned by Each ______________________________________________________ Reporting 7. Sole Dispositive Power 5,095,777 Person With: ______________________________________________________ 8. Shared Dispositive Power 0 _______________________________________________________________________ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,095,777 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 4.77% _______________________________________________________________________ 12. Type of Reporting Person (See Instructions) IA _______________________________________________________________________ Item 1. (a) Name of Issuer NOVOCURE LTD (b) Address of Issuers Principal Executive Offices No. 4 The Forum Grenville Street St. Helier, JE2 4UF Jersey Item 2. (a) Name of Person Filing Baillie Gifford & Co (b) Address of Principal Business Office or, if none, Residence Calton Square 1 Greenside Row Edinburgh EH1 3AN Scotland UK (c) Citizenship Scotland UK (d) Title of Class of Securities Common Stock (e) CUSIP Number G6674U108 Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with rule 240.13d- 1(b)(1)(ii)(E) (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F) (g) A parent holding company or control person in accordance with rule 240.13d-1(b) (1)(ii)(G) (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813) (j) X A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. Ownership. Provide the following information regarding the aggregate number and Percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: see row (9) on page 2. (b) Percent of Class: see row (11) on page 2. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote See row (5) on page 2. (ii) Shared power to vote or to direct the vote See row (6) on page 2 (iii) Sole power to dispose or to direct the disposition of See row (7) on page 2 (iv) Shared power to dispose or to direct the disposition of See row (8) on page 2 Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [x] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief: - the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. - the foreign regulatory scheme applicable to investment advisers is substantially comparable to the functionally equivalent U.S. institution(s). I also undertake to furnish the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. SIGNATURE After reasonable enquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct 07 November 2023 ________________________________ Date Grant Meikle _______________________________________ Signature Grant Meikle Compliance Manager _______________________________________ Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule,including all exhibits. See rule 240.13d- 7 for other parties for whom copies are to be sent. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Get the next $NVCR alert in real time by email

Recent Analyst Ratings for

$NVCR

Date	Price Target	Rating	Analyst
7/25/2025	$14.50	Overweight → Equal Weight	Wells Fargo
7/8/2025	$30.00	Buy	Ladenburg Thalmann
12/2/2024	$18.00 → $30.00	In-line → Outperform	Evercore ISI
10/16/2024	$24.00 → $30.00	Neutral → Buy	H.C. Wainwright
11/20/2023	$15.00	Neutral	JP Morgan
8/28/2023	$85.00 → $25.00	Buy → Neutral	H.C. Wainwright
8/8/2023	$45.00	Neutral → Overweight	Piper Sandler
8/4/2023	$51.00	Outperform	SVB Securities

More analyst ratings

SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

11/9/23 6:15:55 AM ET

$NVCR

Medical/Dental Instruments

Health Care

Get the next $NVCR alert in real time by email

Recent Analyst Ratings for

$NVCR

Date	Price Target	Rating	Analyst
7/25/2025	$14.50	Overweight → Equal Weight	Wells Fargo
7/8/2025	$30.00	Buy	Ladenburg Thalmann
12/2/2024	$18.00 → $30.00	In-line → Outperform	Evercore ISI
10/16/2024	$24.00 → $30.00	Neutral → Buy	H.C. Wainwright
11/20/2023	$15.00	Neutral	JP Morgan
8/28/2023	$85.00 → $25.00	Buy → Neutral	H.C. Wainwright
8/8/2023	$45.00	Neutral → Overweight	Piper Sandler
8/4/2023	$51.00	Outperform	SVB Securities

More analyst ratings

SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$NVCR

SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$NVCR

$NVCR
Insider Purchases

Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

$NVCR
Analyst Ratings

NovoCure downgraded by Wells Fargo with a new price target

Ladenburg Thalmann initiated coverage on NovoCure with a new price target

NovoCure upgraded by Evercore ISI with a new price target

$NVCR
SEC Filings

SEC Form SCHEDULE 13G filed by NovoCure Limited

NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by NovoCure Limited

$NVCR
Press Releases

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Novocure to Report Second Quarter 2025 Financial Results

$NVCR
FDA approvals

October 18, 2024 - FDA Roundup: October 18, 2024

$NVCR
Insider Trading

Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

Chief Human Resources Officer Puri Michal Nath was granted 833 units of Ordinary Shares, increasing direct ownership by 0.51% to 164,514 units (SEC Form 4)

Director Danziger Asaf was granted 833 units of Ordinary Shares, increasing direct ownership by 0.20% to 416,473 units (SEC Form 4)

$NVCR
Leadership Updates

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Novocure Announces Planned CEO Transition

$NVCR
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by NovoCure Limited

Amendment: SEC Form SC 13G/A filed by NovoCure Limited